Literature DB >> 2784306

Polymorphonuclear leucocyte motility in men with ankylosing spondylitis.

C T Pease1, M Fennell, D A Brewerton.   

Abstract

The polymorphonuclear leucocyte (PMN) response to a chemotactic or chemokinetic stimulus is enhanced in men with ankylosing spondylitis (AS). This effect does not parallel the severity of disease activity or the size of the acute phase response, and it is independent of non-steroidal anti-inflammatory drug treatment. Polymorph function is normal in HLA-B27 positive brothers of probands with AS and in other HLA-B27 positive individuals in the absence of disease. Polymorph motility is also normal in patients with psoriasis vulgaris or Crohn's disease, indicating that enhanced PMN motility is not a non-specific consequence of all inflammatory disorders.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2784306      PMCID： PMC1003672          DOI： 10.1136/ard.48.1.35

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


  22 in total

1.  HLA-Bw51 and Behçet's disease.

Authors:  S Ohno; T Asanuma; S Sugiura; A Wakisaka; M Aizawa; K Itakura
Journal:  JAMA       Date:  1978-08-11       Impact factor: 56.272

2.  Chemotaxis in yersinia arthritis. In vitro stimulation of neutrophil migration by HLA--B27 positive and negative sera.

Authors:  H Repo; M Leirisalo; A Tiilikainen; O Laitinen
Journal:  Arthritis Rheum       Date:  1982-06

3.  Leucocyte movement and colchicine treatment in Behcet's disease.

Authors:  N Matsumura; Y Mizushima
Journal:  Lancet       Date:  1975-10-25       Impact factor: 79.321

4.  Inhibition of neutrophil migration by sera from patients with rheumatoid arthritis.

Authors:  A S Kemp; P Roberts-Thomson; S H Neoh; S Brown
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

5.  Enhanced neutrophil migration in vivo HLA B27 positive subjects.

Authors:  P Koivuranta-Vaara; H Repo; M Leirisalo; U Kiistala; T Osterman; H Vapaatalo
Journal:  Ann Rheum Dis       Date:  1984-04       Impact factor: 19.103

6.  Followup study on patients with Reiter's disease and reactive arthritis, with special reference to HLA-B27.

Authors:  M Leirisalo; G Skylv; M Kousa; L M Voipio-Pulkki; H Suoranta; M Nissilä; L Hvidman; E D Nielsen; A Svejgaard; A Tilikainen; O Laitinen
Journal:  Arthritis Rheum       Date:  1982-03

7.  The clinical features and HLA associations of reactive arthritis associated with non-gonococcal urethritis.

Authors:  A C Keat; R N Maini; G D Pegrum; J T Scott
Journal:  Q J Med       Date:  1979-04

8.  The mechanism of hyperchemotaxis in Behçet's disease.

Authors:  A Takeuchi; K Kobayashi; M Mori; Y Mizushima
Journal:  J Rheumatol       Date:  1981 Jan-Feb       Impact factor: 4.666

9.  Chemotaxis in yersinia arthritis. HLA-B27 positive neutrophils show high stimulated motility in vitro.

Authors:  M Leirisalo; H Repo; A Tiilikainen; T U Kosunen; O Laitinen
Journal:  Arthritis Rheum       Date:  1980-09

10.  Effect of high-dose methylprednisolone infusion on polymorphonuclear leukocyte function in patients with systemic lupus erythematosus.

Authors:  H D Perez; R P Kimberley; H B Kaplan; H Edelson; R D Inman; I M Goldstein
Journal:  Arthritis Rheum       Date:  1981-05
View more
  3 in total

1.  Chemotaxis and chemiluminescence responses of synovial fluid polymorphonuclear leucocytes during acute reactive arthritis.

Authors:  M Leirisalo-Repo; A Lauhio; H Repo
Journal:  Ann Rheum Dis       Date:  1990-08       Impact factor: 19.103

Review 2.  Immune functions and inflammatory reactions in HLA-B27 positive subjects.

Authors:  R Tertti; P Toivanen
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

3.  Association of cytokine and matrix metalloproteinase profiles with disease activity and function in ankylosing spondylitis.

Authors:  Derek L Mattey; Jonathan C Packham; Nicola B Nixon; Lucy Coates; Paul Creamer; Sarah Hailwood; Gordon J Taylor; Ashok K Bhalla
Journal:  Arthritis Res Ther       Date:  2012-05-28       Impact factor: 5.156
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.